La Jolla Spa MD, Inc. v. Avidas Pharmaceuticals, LLC

CourtDistrict Court, S.D. California
DecidedOctober 7, 2019
Docket3:17-cv-01124
StatusUnknown

This text of La Jolla Spa MD, Inc. v. Avidas Pharmaceuticals, LLC (La Jolla Spa MD, Inc. v. Avidas Pharmaceuticals, LLC) is published on Counsel Stack Legal Research, covering District Court, S.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
La Jolla Spa MD, Inc. v. Avidas Pharmaceuticals, LLC, (S.D. Cal. 2019).

Opinion

1 2 3 4 5 6 7 8 UNITED STATES DISTRICT COURT 9 SOUTHERN DISTRICT OF CALIFORNIA 10 11 LA JOLLA SPA MD, INC, Case No. 3:17-CV-01124-MMA-WVG

12 Plaintiff, ORDER DENYING 13 v. DEFENDANT’S MOTION TO DISMISS OR, IN THE 14 AVIDAS PHARMACEUTICALS, LLC, ALTERNATIVE, FOR SUMMARY 15 Defendant. JUDGMENT

16 Doc. No. 96 17 18 19 20 La Jolla Spa MD, Inc. (“Plaintiff”) filed a Third Amended Complaint 21 (“Complaint”) against Avidas Pharmaceuticals, LLC (“Defendant”) for breach of 22 contract. See Doc. No. 87 (“Compl.”). Defendant filed an Answer. See Doc. No. 90 23 (“Answer”). Defendant moves to dismiss Plaintiff’s Complaint for lack of subject-matter 24 jurisdiction as well as for failure to state a claim under Federal Rules of Civil Procedure 25 12(b)(1) and 12(b)(6). See Doc. No. 96. Defendant moves in the alternative for 26 summary judgment under Federal Rule of Civil Procedure 56. See id. Plaintiff filed an 27 opposition to the motion, and Defendant replied. See Doc Nos. 97, 99. The Court found 28 the matter suitable for determination on the papers and without oral argument pursuant to 1 Civil Local Rule 7.1.d.1. See Doc. No. 101. For the reasons set forth below, the Court 2 DENIES Defendant’s motion in its entirety. 3 BACKGROUND1 4 This action arises out of a contractual relationship between the parties regarding 5 Vitaphenol skincare products that the parties later terminated. The central issues arise 6 from actions after termination of the relationship. 7 Plaintiff and Defendant entered into two separate but related contracts on August 8 19, 2008, which were signed by both parties by October 14, 2008. Compl. ¶ 2; Compl. 9 Ex. 1, 2; Answer ¶ 2. The first contract was the Sales and Distribution Agreement 10 (“Sales Agreement”). Compl. ¶ 2; Compl. Ex. 1; Answer ¶ 2. The second contract was 11 the Know-How and Trademark License and Purchase Agreement, partially supplemented 12 by the Modified Know-How and Trademark License and Purchase Agreement 13 (collectively referred to as the “Know-How Agreement”). Compl. ¶ 2; Compl. Ex. 2. 14 I. Sales Agreement Terms 15 Under the terms of the Sales Agreement, Defendant “was to pay Plaintiff for the 16 cost of inventory sold plus a royalty of 8%.” Compl. ¶ 5. Defendant had the power to 17 terminate the agreement “upon sixty days prior written notice in the event it determines in 18 its sole discretion that continuation of its efforts to promote and sell the Products is no 19 longer in its best business interests.” Compl. Ex. 1 at 4(c). 20 21 1 Regarding the motion to dismiss for lack of subject-matter jurisdiction, the Court analyzes a facial 22 attack by accepting the allegations of the complaint as true and drawing all reasonable inferences in favor of Plaintiff. See Doe v. Holy See, 557 F.3d 1066, 1073 (9th Cir. 2009) (per curiam) (citing Wolfe 23 v. Strankman, 392 F.3d 358, 362 (9th Cir. 2004). Because the Court construes the motion to dismiss for failure to state a claim as a motion for 24 judgment on the pleadings, see infra, the Court must accept the complaint’s allegations as true and the 25 answer’s allegations that contradict the complaint’s allegations as false. Hoeft v. Tucson Unified Sch. Dist., 967 F.2d 1298, 1301 n.2 (9th Cir. 1992). 26 Regarding the motion for summary judgment, these material facts are taken from the parties’ separate statements and responses thereto, as well as the supporting declarations and exhibits. Where a 27 material fact is in dispute, it will be so noted. Particular disputed material facts that are not recited in this section may be discussed infra. Facts that are immaterial for purposes of resolving the current 28 1 Upon early termination, the agreement required the following: 2 In the event of early termination in whole or in respect of any product, 3 Avidas shall return all unsold inventory to YGE or unsold Inventory of terminated product(s) (SKUs) if the Agreement is terminated in respect of 4 fewer than all products. Upon early termination of this Agreement Avidas 5 shall immediately cease its promotional activities for the Vitaphenol Products and discontinue any use of the Vitaphenol and La Jolla Spa MD 6 Trademarks. After any early termination of this Agreement YGB shall 7 retain the right to the Vitaphenol Products but will remove any information bearing Avidas’s Trademarks and logos from Product and Product materials. 8

9 Id. at 4(g). The agreement further specified payments and royalties concerning sold 10 inventory by Defendant upon termination: “Upon termination, the provisions of this 11 Agreement concerning payment and royalties on Inventory sold to Avidas’s customers 12 shall continue until such payments have been made.” Id. at 4(h). 13 II. Know-How Agreement Terms 14 Under the terms of the Know-How Agreement, Defendant was obligated to pay for 15 the license of the “know-how” and trademark for Vitaphenol through an 8% royalty 16 payment on all Vitaphenol products until the royalty payments totaled $1,500,000; 17 thereafter, Defendant would then pay a 5% royalty. Compl. ¶¶ 5, 7, 13; Compl. Ex. 2 at 18 4(a)–(c). The Agreement allowed for Defendant to “transfer[] ownership of, or license[], 19 the Know-How and Vitaphenol trademark,” but required Defendant “to obligate the 20 purchaser or licensee to continue paying such five percent (5%) royalty.” Compl. ¶ 7; 21 Compl. Ex. 2 at 4(b). As with the Sales Agreement, the Know-How Agreement gives 22 Defendant the power to terminate the agreement “upon sixty days prior written notice in 23 the event it determines in its sole discretion that continuation of its efforts to promote and 24 sell the Products is no longer in its best business interest.” Complaint Ex. 2 at 8(b). 25 Upon early termination, the Agreement stated that Defendant 26 shall have the right to dispose of its stock of Product and shall have the right to manufacture such finished Product as may be necessary to balance out 27 inventory or to convert raw materials, or goods in process, into finished 28 1 goods. All sales made pursuant to this section shall be subject to the payments of royalties as provided above. 2

3 Id. at 8(f). If Defendant provides the sixty-day notice of termination pursuant to Section 4 8(b) of the Agreement and has not met the $1,500,000 royalty payment threshold, 5 Defendant “shall discontinue its use of the Vitaphenol trademark and the Know-How and 6 all rights in respect of the Know-How and Vitaphenol trademark shall revert back to 7 York-Goldman.” Id. at 8(g). However, if the Defendant has met the $1,500,000 8 threshold, then Defendant “has no further obligation to York-Goldman unless Avidas 9 resumes sale of the Vitaphenol Products or conveys or licenses the Know-How and, or 10 Vitaphenol trademark to a third party in which case the obligations” regarding the 11 transfer of ownership or license, supra, take effect. Id. 12 III. Defendant’s Agreement with a Third-Party 13 Around August 25, 2010, Defendant and SciDerma Medical, LLC (“SciDerma”) 14 entered into an Inventory and License Agreement. Compl. ¶ 11. Under the agreement, 15 SciDerma “became the exclusive licensee of the Vitaphenol products in the United States 16 . . . and Canada.” Id. However, Defendant “did not pay Plaintiff pursuant to the Contract 17 for the inventory purchased by SciDerma . . . in connection with the Inventory and 18 License Agreement. Plaintiff was unaware of the existence and terms of the Inventory 19 and License Agreement until Avidas disclosed it in a Court filing on December 3, 2018.” 20 Id. (citing Doc. No. 47-2 Ex. L.). 21 IV. Termination and Breach 22 Defendant stopped paying royalties “around mid-2014.” Compl. ¶ 12.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

PRATT & OTHERS v. Law & Campbell
13 U.S. 456 (Supreme Court, 1815)
Land v. Dollar
330 U.S. 731 (Supreme Court, 1947)
First Nat. Bank of Ariz. v. Cities Service Co.
391 U.S. 253 (Supreme Court, 1968)
Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Narayan v. EGL, INC.
616 F.3d 895 (Ninth Circuit, 2010)
Alvera M. Aldabe v. Charles D. Aldabe
616 F.2d 1089 (Ninth Circuit, 1980)
Richard Augustine v. United States
704 F.2d 1074 (Ninth Circuit, 1983)
Brian Barlow v. Officer George Ground, I.D. 9129
943 F.2d 1132 (Ninth Circuit, 1991)
Robin Orr v. Bank of America, Nt & Sa
285 F.3d 764 (Ninth Circuit, 2002)

Cite This Page — Counsel Stack

Bluebook (online)
La Jolla Spa MD, Inc. v. Avidas Pharmaceuticals, LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/la-jolla-spa-md-inc-v-avidas-pharmaceuticals-llc-casd-2019.